Hemostemix Inc (CVE:HEM)’s share price was down 10% during mid-day trading on Friday . The company traded as low as C$0.09 and last traded at C$0.09. Approximately 157,167 shares traded hands during trading, an increase of 35% from the average daily volume of 116,540 shares. The stock had previously closed at C$0.10.
ILLEGAL ACTIVITY NOTICE: “Hemostemix (HEM) Shares Down 10%” was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2019/01/11/hemostemix-hem-shares-down-10.html.
About Hemostemix (CVE:HEM)
Hemostemix Inc, a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia.
Further Reading: The mechanics of the bid-ask spread in trading
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.